Literature DB >> 2510345

Plasminogen activators and plasminogen activator inhibitors in liver deficiencies caused by chronic alcoholism or infectious hepatitis.

C Tran-Thang1, J Fasel-Felley, G Pralong, J R Hofstetter, F Bachmann, E K Kruithof.   

Abstract

Plasma concentrations of tissue-type plasminogen activator (t-PA), urokinase (u-PA), plasminogen activator inhibitor 1 (PAI-1) and PAI-2 were studied in 53 patients with liver deficiency caused by chronic alcoholism (n = 40), viral hepatitis (n = 10) or malignant disease of the liver (n = 3) and compared to that of a control group (n = 20) of healthy subjects. u-PA and PAI-1 levels were significantly increased in all patients with chronic alcoholism, whereas high t-PA was only observed in combination with disturbed liver function tests or with liver cirrhosis (two and six-fold above control values, respectively). A good correlation was observed between t-PA and gamma glutamyl transferase (r = 0.615; p less than 0.001). In patients with infectious hepatitis or with malignant disease of the liver t-PA was normal whereas u-PA and PAI-1 were increased. PAI-2 levels were close to or below the detection limit (15 ng/ml) in the control group and in most patients. However, in two patients with alcohol induced cirrhosis PAI-2 levels were approximately 45 ng/ml and in one patient with hepatocarcinoma even 66 ng/ml. Thus, in liver disease, marked elevations of t-PA, u-PA and PAI-1 levels may occur, with increased PAI-1 as an early marker of liver defects and t-PA a marker of severe liver defects.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2510345

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  12 in total

Review 1.  Mechanisms and cell signaling in alcoholic liver disease.

Authors:  Juliane I Beier; Craig J McClain
Journal:  Biol Chem       Date:  2010-11       Impact factor: 3.915

2.  Distribution of plasminogen activator inhibitor in normal liver, cirrhotic liver, and liver with metastases.

Authors:  P Fitch; B Bennett; N A Booth; A Croll; S W Ewen
Journal:  J Clin Pathol       Date:  1994-03       Impact factor: 3.411

Review 3.  Alcoholic liver disease and the potential role of plasminogen activator inhibitor-1 and fibrin metabolism.

Authors:  Juliane I Beier; Gavin E Arteel
Journal:  Exp Biol Med (Maywood)       Date:  2012-01

Review 4.  Advances in alcoholic liver disease.

Authors:  Juliane I Beier; Gavin E Arteel; Craig J McClain
Journal:  Curr Gastroenterol Rep       Date:  2011-02

Review 5.  Ethanol and liver: recent insights into the mechanisms of ethanol-induced fatty liver.

Authors:  Jinyao Liu
Journal:  World J Gastroenterol       Date:  2014-10-28       Impact factor: 5.742

6.  Elevated urokinase-type plasminogen activator plasma levels are associated with deterioration of liver function but not with hepatocellular carcinoma.

Authors:  S Sato; T Higashi; S Ouguchi; N Hino; T Tsuji
Journal:  J Gastroenterol       Date:  1994-12       Impact factor: 7.527

7.  Tissue plasminogen activator, plasminogen activator inhibitors, and activator-inhibitor complex in liver disease.

Authors:  K Leiper; A Croll; N A Booth; N R Moore; T Sinclair; B Bennett
Journal:  J Clin Pathol       Date:  1994-03       Impact factor: 3.411

Review 8.  New role of plasminogen activator inhibitor-1 in alcohol-induced liver injury.

Authors:  Gavin E Arteel
Journal:  J Gastroenterol Hepatol       Date:  2008-03       Impact factor: 4.029

9.  Clinical evaluation of tissue plasminogen activator (t-PA) levels in patients with liver diseases.

Authors:  K Okabe; I Kato; S Sato; T Kashiwabara; S Furuta; H Sato; K Tanikawa; R Kumashiro; M Kanayama
Journal:  Gastroenterol Jpn       Date:  1992-02

10.  Acute alcohol-induced liver injury.

Authors:  Veronica L Massey; Gavin E Arteel
Journal:  Front Physiol       Date:  2012-06-12       Impact factor: 4.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.